SuperworthbioAffinity Technologies BIAF
- Market cap
- $1.5M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.3×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $5.9M
- −23% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −764.4%
bioAffinity Technologies trades at 0.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $5.9M over the last twelve months, down 23% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $298.5K+25855% | $2.2M+94246% | $2.4M+261180% | $2.4M+12047% | $2.4M+687% | $2.2M−0% | $1.9M−23% | $1.3M−47% | $1.4M−39% | $1.6M−28% | $1.4M−27% | $1.5M+19% | |
| Cost of revenue | $74.7K+51067% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | $223.8K+22189% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $330.4K+3% | $432.8K+124% | $393.6K+7% | $402.4K+20% | $274.5K−17% | $390.7K−10% | $367.4K−7% | $311.4K−23% | $330.6K+20% | $374K−4% | $349.7K−5% | $361.6K+16% |
| SG&A | $2M+240% | $2.2M+87% | $2.2M+90% | $2.5M+76% | $2.4M+17% | $2.9M+32% | $2.5M+12% | $2.2M−10% | $2.2M−7% | $3M+4% | $3.2M+32% | $2.9M+29% |
| −$2.3M+135% | −$2.3M+44% | −$1.9M+25% | −$2.1M+17% | −$2M−14% | −$2.9M+26% | −$2.6M+35% | −$2.5M+21% | −$2.3M+16% | −$3.1M+7% | −$3.6M+38% | −$3.3M+33% | |
| Interest expense | $8.8K−99% | $25.3K−72% | $23.6K+1323% | $22.2K+1536% | $21.6K+146% | $25K−1% | $15.5K−34% | $10.5K−53% | $5.4K−75% | $13.1K−48% | $14.7K−5% | $11.7K+12% |
| Pre-tax income | −$2.3M−54% | −$2.4M+42% | −$2M+29% | −$2.1M+21% | −$2M−13% | −$3M+25% | −$2.7M+35% | −$4M+92% | −$5M+153% | −$3.1M+6% | −$3.6M+37% | −$3.4M−17% |
| $2.3K+665% | $2.3K | $3.7K−69% | $5.4K+18% | $2.6K+12% | $0 | $8.7K+137% | $29K+435% | $3.2K+24% | $3.2K | n/a | n/a | |
| Net income | −$2.3M−53% | −$2.4M+42% | −$2M+28% | −$2.1M+21% | −$2M−13% | −$3M+25% | −$2.7M+36% | −$4.1M+92% | −$5.1M+152% | −$3.1M+6% | −$3.6M+37% | −$3.4M−17% |
| −$117.00−78% | −$112.50+25% | −$90.00+11% | −$85.50−5% | −$72.60−38% | −$90.30−20% | −$72.00−20% | −$76.05−11% | −$71.10−2% | −$10.65−88% | −$12.15−83% | −$9.60−87% | |
| 19.3K+107% | 20.7K+12% | 22K+18% | 25.3K+34% | 27.5K+42% | 32.8K+58% | 36.1K+64% | 53.4K+111% | 71.1K+158% | 296K+801% | 299.7K+730% | 348.5K+553% |
Revenue: Q1 FY22: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY22: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY22: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY22: 6 months less the 3 months printed beside them.
EPS, diluted: 5 periods, Q1 FY22 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY22: share-days: the 6-month average less the second quarter's. 4 periods, Q4 FY22 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest bioAffinity Technologies' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BIAFbioAffinity Technologies | $1.5M | n/m | n/a | 0.3× | −23% | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $7.7M | 47.5× | 9.6× | 2.8× | +40% | 4.7% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| GTIMGood Times Restaurants | $13.6M | 6.1× | 13.6× | 0.1× | −6% | 1.7% | |
| Peer median | $8.7M | 6.1× | 11.3× | 0.4× | −6% | 4.7% |
More on bioAffinity Technologies
Each number over time
Where it ranks
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .